Zero Candida lists on Frankfurt Stock Exchange

FemTech medical device company Zero Candida Technologies has listed on the Frankfurt Stock Exchange (FSE) under the trading symbol “9L2”.

The listing expands Zero Candida’s global presence, now cross-listed on both the TSX Venture Exchange and the FSE.

The company is developing an AI-driven, tampon-like device that uses a therapeutic light source with a selected wave-length and intensity to effectively treat the Candida fungus with a demonstrated 99.999 per cent success rate.

Founder & CEO, Eli Ben Haroosh, said: “Listing on the Frankfurt Stock Exchange represents a crucial step forward for Zero Candida. The European investment community has been captivated by our innovations from the start, and this listing allows them to directly be a part of our vision and growth journey.

“With our hospital partnerships and patent applications progressing across Europe, we’re thrilled to expand our capital markets presence and accelerate our mission of revolutionising women’s health.”

The company has said that its listing on the FSE provides it with a strategic opportunity to connect with international investors and further establish its presence in Europe and beyond.